- Free from Publisher K Hermansen, M Davies, T Derezinski, G … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and
from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of
participants achieved an A1C ≤7.0%, but the proportion achieving this ... Cited by 224 - Related articles - BL Direct - All 9 versions
T Haak, A Tiengo, E Draeger, M Suntum, W … - Diabetes Obesity and Metabolism, 2005 - fe-inzichten.nl Aim: The aim of this study was to compare the efficacy and safety of a
basal-bolus insulin regimen comprising either insulin detemir or neural
protamine hagedorn (NPH) insulin in combination with mealtime insulin ... Cited by 193 - Related articles - View as HTML - All 5 versions
K Rašlová, M Bogoev, I Raz, G Leth, MA Gall … - Diabetes research and clinical practice, 2004 - Elsevier This trial compared the efficacy and safety of basal-bolus therapy using either
the soluble basal insulin analogue insulin detemir (IDet) in combination with
meal-time rapid-acting analogue insulin aspart (IAsp), or NPH insulin (NPH) ... Cited by 160 - Related articles - All 8 versions
A Philis-Tsimikas, G Charpentier, P Clauson, … - Clinical therapeutics, 2006 - Elsevier This 20-week, multicenter, randomized, open-label, 3-arm, parallel-group trial
was conducted at 91 centers across Europe and the United States. Men and women
were eligible for participation if they were aged ≥18 years, had a body ... Cited by 84 - Related articles - All 4 versions
B Weight, S Monitoring - members.medscape.com In each group, ~65% received combination OGLD therapy (mostly metformin plus
secretagogue). Respective use of monotherapy in the insulin detemir and NPH
insulin groups was 28.7 and 26.5% for secretagogues and 5.9 and 8.0% for ... Related articles
ID Titration, E Points, S Analyses - members.medscape.com In this parallel-group trial, 475 insulin-naïve people with type 2 diabetes
were randomized and treated (with informed consent) to twice-daily subcutaneous
insulin detemir (Levemir; Novo Nordisk, Bagsvaerd, Denmark) or human NPH ... Related articles
FD Care - medscape.com Delays in insulin initiation arise from fear of injections, psychological issues
such as nonacceptance of treatment failure, and concerns about hypoglycemia and
weight gain. [10-12] However, blood glucose control is improved by ... Related articles - All 3 versions
H Yki-Järvinen, R Kauppinen-Mäkelin, M … - Diabetologia, 2006 - Springer Page 1. Diabetologia (2006) 49: 442–451 DOI 10.1007/s00125-005-0132-0 ARTICLE H.
Yki-Järvinen . R. Kauppinen-Mäkelin . M. Tiikkainen . M. Vähätalo . ... Cited by 156 - Related articles - BL Direct - All 7 versions
D Russell-Jones, R Simpson, B Hylleberg, E … - Clinical therapeutics, 2004 - Elsevier Methods: This was a 6-month, prospective, randomized, open-label, controlled,
parallel-group trial conducted at 92 sites in Europe and Australia. The trial
population included men and women with type 1 DM for at least 1 year aged ... Cited by 122 - Related articles - All 4 versions
- ►novonordisk.co.uk [PDF] T Heise, L Nosek, BB Rønn, L Endahl, L … - Diabetes, 2004 - Am Diabetes Assoc The aim of this randomized double-blind study was to compare the within-subject
variability of the glucose-lowering effect of a novel insulin analog, insulin
detemir, with that of insulin glargine and NPH insulin in people with type ... Cited by 293 - Related articles - BL Direct - All 13 versions
